Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

Multiple myeloma (MM) is a plasma cell neoplasm that results in over 11,000 deaths in the United States annually. The backbone therapy for the treatment of MM patients almost always includes combinations with corticosteroids such as dexamethasone (DEX). We found that DEX in combination with selinexo...

Descripción completa

Detalles Bibliográficos
Autores principales: Argueta, Christian, Kashyap, Trinayan, Klebanov, Boris, Unger, Thaddeus J., Guo, Cathy, Harrington, Susie, Baloglu, Erkan, Lee, Margaret, Senapedis, William, Shacham, Sharon, Landesman, Yosef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986633/
https://www.ncbi.nlm.nih.gov/pubmed/29876006
http://dx.doi.org/10.18632/oncotarget.25368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986633/
https://www.ncbi.nlm.nih.gov/pubmed/29876006
http://dx.doi.org/10.18632/oncotarget.25368

Ejemplares similares